The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSuperdry Regulatory News (SDRY)

Share Price Information for Superdry (SDRY)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 7.40
Bid: 7.40
Ask: 7.45
Change: 0.66 (9.79%)
Spread: 0.05 (0.676%)
Open: 6.45
High: 7.50
Low: 6.45
Prev. Close: 6.74
SDRY Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Rule 2.8 Announcement

28 Mar 2024 16:37

RNS Number : 7874I
Julian Marc Dunkerton
28 March 2024
 

THIS IS AN ANNOUNCEMENT FALLING UNDER RULE 2.8 OF THE CITY CODE ON TAKEOVERS AND MERGERS (THE "CODE")

 

FOR IMMEDIATE RELEASE

 

28 March 2024

 

Statement Regarding Superdry plc

 

Following a period of engagement with the Transaction Committee (being the Company's Board of Directors excluding Julian Dunkerton) of Superdry plc ("Superdry" or the "Company"), Julian Dunkerton, Founder and Chief Executive Officer of Superdry, and the Transaction Committee have, together, concluded that a takeover offer from Julian Dunkerton for the Company is unlikely to deliver an outcome for shareholders, or stakeholders more broadly, that the Transaction Committee and Julian Dunkerton are confident can be executed in the context of the Company's ongoing work on its turnaround plan and material cost saving options.

However, Julian Dunkerton remains fully committed to the Company over the long-term and is in discussions with the Company in respect of alternative structures, including a possible equity raise fully underwritten by Julian Dunkerton, which would provide additional liquidity headroom for the Company's turnaround plan. It is expected that any equity raise would be at a very material discount to the current share price, require shareholder approval of a Rule 9 waiver (as referred in Note 1 of the Notes on Dispensations from Rule 9 of the Code) and be conditional on a de-listing of the Company. A further announcement will be made as appropriate. There can be no certainty that a transaction with Julian Dunkerton will be agreed.

This is a statement to which Rule 2.8 of the Code applies.

For the purposes of Note 2 on Rule 2.8 of the Code, Julian Dunkerton and any person(s) acting in concert with him reserve the right to make or participate in an offer for Superdry (and/or take any other actions which would otherwise be restricted under Rule 2.8 of the Code) within the next six months following the date of this announcement in the following circumstances:

 

(i) with the agreement of the Transaction Committee;

 

(ii) following the announcement of a firm intention to make an offer for Superdry by or on behalf of a third party;

 

(iii) following the announcement by Superdry of a Rule 9 waiver proposal (as described in Note 1 of the Notes on Dispensations from Rule 9 of the Takeover Code) (excluding a Rule 9 waiver proposal by Julian Dunkerton) or a reverse takeover (as defined in the Code); or

 

(iv) where the Takeover Panel has determined that there has been a material change of circumstances.

 

Enquiries:

N. M. Rothschild & Sons Limited (Financial Adviser to Julian Dunkerton)

John Byrne

Charles Fenwick

+44 (0)121 600 5252

Important notice related to Financial Adviser

N. M. Rothschild & Sons Limited ("Rothschild & Co"), which is authorised and regulated by the Financial Conduct Authority in the United Kingdom, is acting exclusively for Julian Dunkerton and for no one else in connection with the subject matter of this announcement and will not be responsible to anyone other than Julian Dunkerton for providing the protections afforded to its clients or for providing advice in connection with the subject matter of this announcement.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
OUPEAKDPAFELEFA
Date   Source Headline
21st Jul 202011:29 amRNSHolding(s) in Company
20th Jul 20202:12 pmRNSHolding(s) in Company
14th Jul 202010:03 amRNSDirector/PDMR Shareholding
2nd Jul 202010:34 amRNSHolding(s) in Company
2nd Jul 202010:23 amRNSHolding(s) in Company
2nd Jul 20209:47 amRNSHolding(s) in Company
30th Jun 202010:21 amRNSTotal Voting Rights
29th Jun 20209:20 amRNSHolding(s) in Company
24th Jun 20204:41 pmRNSSecond Price Monitoring Extn
24th Jun 20204:36 pmRNSPrice Monitoring Extension
18th Jun 20207:00 amRNSStatement re China Joint Venture
16th Jun 20209:14 amRNSDirector/PDMR Shareholding
2nd Jun 202011:29 amRNSHolding(s) in Company
29th May 202012:02 pmRNSPrice Monitoring Extension
29th May 20209:28 amRNSTotal Voting Rights
26th May 202012:02 pmRNSPrice Monitoring Extension
22nd May 20204:15 pmRNSHolding(s) in Company
15th May 20204:41 pmRNSSecond Price Monitoring Extn
15th May 20204:36 pmRNSPrice Monitoring Extension
14th May 20209:48 amRNSDirector/PDMR Shareholding
12th May 202012:02 pmRNSPrice Monitoring Extension
7th May 20207:00 amRNSTrading Statement
30th Apr 20202:00 pmRNSTotal Voting Rights
22nd Apr 202012:07 pmRNSSecond Price Monitoring Extn
22nd Apr 202012:02 pmRNSPrice Monitoring Extension
15th Apr 20202:15 pmRNSDirector/PDMR Shareholding
9th Apr 20209:00 amRNSDirector Declaration
3rd Apr 20209:04 amRNSHolding(s) in Company
31st Mar 202011:28 amRNSTotal Voting Rights
31st Mar 202010:46 amRNSHolding(s) in Company
27th Mar 20204:37 pmRNSPrice Monitoring Extension
26th Mar 202012:02 pmRNSPrice Monitoring Extension
25th Mar 20204:42 pmRNSSecond Price Monitoring Extn
25th Mar 20204:37 pmRNSPrice Monitoring Extension
24th Mar 202010:15 amRNSHolding(s) in Company
23rd Mar 20202:34 pmRNSBlock listing Interim Review
18th Mar 20207:00 amRNSStatement re Current trading and COVID-19 update
16th Mar 202010:42 amRNSDirector/PDMR Shareholding
4th Mar 20209:21 amRNSHolding(s) in Company
2nd Mar 20204:17 pmRNSHolding(s) in Company
28th Feb 20208:54 amRNSTotal Voting Rights
14th Feb 202011:58 amRNSDirector/PDMR Shareholding
31st Jan 20203:42 pmRNSTotal Voting Rights
28th Jan 20202:25 pmRNSDirector Declaration
28th Jan 20209:18 amRNSDirector/PDMR Shareholding
20th Jan 20203:35 pmRNSDirector/PDMR Shareholding
14th Jan 20209:40 amRNSDirector/PDMR Shareholding
10th Jan 20207:00 amRNSTrading Statement
31st Dec 201912:23 pmRNSTotal Voting Rights
23rd Dec 20193:57 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.